GLP-1 Drug Use and Major Cardiovascular Events: Large Population Analysis
Large-scale population analysis of GLP-1 drug association with major cardiovascular events confirms significant reduction in heart attack, stroke, and cardiovascular death.
Quick Facts
What This Study Found
Large-scale population analysis of GLP-1 drug association with major cardiovascular events confirms significant reduction in heart attack, stroke, and cardiovascular death.
Key Numbers
Comprehensive search through March 2025 across four databases. No significant association with diabetic retinopathy development or progression.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide therapeutic knowledge.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding Large-scale population analysis of GLP-1 drug association with major cardiovascular events confirms
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.
- Published In:
- Frontiers in medicine, 12, 1639704 (2025)
- Authors:
- Alwafi, Hassan, Al-Harbi, Sarah Saleh, Aladwani, Ghada Ahmad, Alsanosi, Safaa M, Oyelade, Tope, Almalki, Fahd, Thalib, Husna Irfan, Naser, Abdallah Y, Alfahmi, Manal Z, AlOtaibi, Basil, Fuad, Samra, Zubair, Mohammed Talha Mohammed, Aldhahir, Abdulelah M, Insani, Widya N, Alqarni, Abdullah A, Alqahtani, Jaber S, Ashoor, Deema S, Dairi, Mohammad Saleh
- Database ID:
- RPEP-09914
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Large-scale population analysis of GLP-1 drug association with major cardiovascular events confirms significant reduction in heart attack, stroke, and cardiovascular death.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09914APA
Alwafi, Hassan; Al-Harbi, Sarah Saleh; Aladwani, Ghada Ahmad; Alsanosi, Safaa M; Oyelade, Tope; Almalki, Fahd; Thalib, Husna Irfan; Naser, Abdallah Y; Alfahmi, Manal Z; AlOtaibi, Basil; Fuad, Samra; Zubair, Mohammed Talha Mohammed; Aldhahir, Abdulelah M; Insani, Widya N; Alqarni, Abdullah A; Alqahtani, Jaber S; Ashoor, Deema S; Dairi, Mohammad Saleh. (2025). Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.. Frontiers in medicine, 12, 1639704. https://doi.org/10.3389/fmed.2025.1639704
MLA
Alwafi, Hassan, et al. "Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.." Frontiers in medicine, 2025. https://doi.org/10.3389/fmed.2025.1639704
RethinkPeptides
RethinkPeptides Research Database. "Association of glucagon-like peptide-1 (GLP-1) receptor agon..." RPEP-09914. Retrieved from https://rethinkpeptides.com/research/alwafi-2025-association-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.